These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 23560807)
1. Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Schaefer SM; Süsal C; Sommerer C; Zeier M; Morath C Expert Opin Pharmacother; 2013 Jun; 14(8):1029-41. PubMed ID: 23560807 [TBL] [Abstract][Full Text] [Related]
2. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Helal I; Chan L Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737 [TBL] [Abstract][Full Text] [Related]
3. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Armenti VT; Radomski JS; Moritz MJ; Gaughan WJ; Philips LZ; McGrory CH; Coscia LA; Clin Transpl; 2002; ():121-30. PubMed ID: 12971441 [TBL] [Abstract][Full Text] [Related]
4. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546 [TBL] [Abstract][Full Text] [Related]
11. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive strategies to improve outcomes of kidney transplantation. Tang IY; Meier-Kriesche HU; Kaplan B Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271 [TBL] [Abstract][Full Text] [Related]
13. A drug safety evaluation of everolimus in kidney transplantation. Holdaas H; Midtvedt K; Åsberg A Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349 [TBL] [Abstract][Full Text] [Related]
14. Current and evolving immunosuppressive regimens in kidney transplantation. Gaston RS Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S3-21. PubMed ID: 16567239 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction in deceased donor kidney transplantation. Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271 [TBL] [Abstract][Full Text] [Related]
16. Cost-effective immunosuppressive options for solid organ transplantation: a guide to lower cost for the renal transplant recipient in the USA. Farney AC; Doares W; Kaczmorski S; Rogers J; Stratta RJ Immunotherapy; 2010 Nov; 2(6):879-88. PubMed ID: 21091118 [TBL] [Abstract][Full Text] [Related]
17. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? Nashan B Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616 [TBL] [Abstract][Full Text] [Related]
19. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection. Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D Clin Transpl; 2011; ():381-7. PubMed ID: 22755435 [TBL] [Abstract][Full Text] [Related]
20. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]